Microtest and Antisoma Form Manufacturing Pact
ePT--the Electronic Newsletter of Pharmaceutical Technology
Agawam, MA (Mar. 26)-Contract manufacturing and testing laboratory Microtest signed a manufacturing deal with Antisoma to produce AS1411, a new drug being developed for the treatment of various cancers.
Agawam, MA (Mar. 26)-Contract manufacturer and testing laboratory Microtest (www.microtestlabs.com) signed a manufacturing deal with Antisoma (London, www.antisoma.com) to produce AS1411, a new drug being developed to treat various cancers.
Microtest will formulate and aseptically fill and finish AS1411 for Phase II clinical trials. Microtest also will perform stability testing on the product.
Microtest recently invested $7.5 million to expand its pharmaceutical testing services and fill-and-finish contract-manufacturing capabilities. The expansion included new pharmaceutical testing laboratories and new aseptic fill and finish manufacturing facilities.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
